文献速递外周动脉疾病

慢性肾脏病与外周动脉疾病患者凝血谱的变异性

Variability in Coagulation Profiles in Patients with Chronic Kidney Disease and Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2025-01-28

本研究前瞻性纳入2020年12月至2023年接受血运重建的外周动脉疾病患者254例,按肾小球滤过率(GFR)分为>60、30-59、<30 mL/min三组,用血栓弹力图(TEG)评估凝血谱。肾功能下降者纤维蛋白原水平和血凝块强度更高,但出血事件(P=0.436)和动脉血栓事件(P=0.095)在各GFR组间无显著差异。

要点

  • 肾功能下降患者TEG显示相对高凝状态,纤维蛋白原水平和血凝块强度更高。
  • 双联抗血小板治疗(DAPT)者凝血标志物水平低于单联抗血小板治疗(MAPT)者。
  • 各GFR组间出血事件(P=0.436)和动脉血栓事件(P=0.095)无显著差异。

核心结论

  • 肾功能下降患者较肾功能正常者呈现相对高凝状态,表现为纤维蛋白原水平升高和血凝块强度增强。
  • DAPT与较低的凝血标志物水平相关,但血小板反应性在各GFR组间相似。
  • 这些实验室发现未转化为临床事件增加,各GFR组间出血事件(P=0.436)和动脉血栓事件(P=0.095)无显著差异。

研究设计与样本

  • 前瞻性评估接受血运重建的外周动脉疾病患者(2020年12月至2023年)。
  • 按GFR分为3组:>60 mL/min、30-59 mL/min、<30 mL/min。
  • 术前血样分析TEG参数,包括最大振幅(MA)、枸橼酸化功能性纤维蛋白原(CFF)和功能性纤维蛋白原水平(FLEV)。
  • 统计采用Kruskal-Wallis检验。
  • 共254例患者:GFR>60组182例,GFR 30-59组56例,GFR<30组16例。

主要发现

  • CRT MA:GFR>60组62.80 mm vs GFR 30-59组65.85 mm vs GFR<30组67.85 mm,P=0.0021。
  • CK MA:GFR>60组61.10 mm vs GFR 30-59组64.00 mm vs GFR<30组66.70 mm,P=0.0063。
  • CFF MA:GFR>60组21.40 mm vs GFR 30-59组24.10 mm vs GFR<30组33.70 mm,P=0.0017。
  • CFF FLEV:GFR>60组390.5 mg/dL vs GFR 30-59组487.2 mg/dL vs GFR<30组556.6 mg/dL,P=0.0029。
  • 接受MAPT的患者较DAPT者凝血标志物水平持续更高,尤其在严重肾功能损害(GFR<30)时。

关键数值与推荐

  • CRT MA:GFR>60组62.80 mm vs GFR 30-59组65.85 mm vs GFR<30组67.85 mm,P=0.0021。
  • CK MA:GFR>60组61.10 mm vs GFR 30-59组64.00 mm vs GFR<30组66.70 mm,P=0.0063。
  • CFF MA:GFR>60组21.40 mm vs GFR 30-59组24.10 mm vs GFR<30组33.70 mm,P=0.0017。
  • CFF FLEV:GFR>60组390.5 mg/dL vs GFR 30-59组487.2 mg/dL vs GFR<30组556.6 mg/dL,P=0.0029。
  • 出血事件P=0.436,动脉血栓事件P=0.095,各GFR组间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic Kidney Disease (CKD) has been associated with a prothrombotic state. CKD affects hemostasis through altered platelet function and coagulation factors. Traditional tests provide limited insight into these changes. We used Thromboelastography (TEG) to evaluate coagulation profiles in CKD and non-CKD patients, comparing parameters based on glomerular filtration rate (GFR) to better understand clotting dynamics. The aim of the study was to evaluate coagulation profiles in patients across GFR categories using Thromboelastography (TEG), which enables comprehensive assessment of clot formation dynamics. METHODS: We prospectively evaluated patients with peripheral artery disease undergoing revascularization (December 2020-2023). Patients were stratified by GFR into 3 groups: >60 mL/min, 30-59 mL/min, and <30 mL/min. Pre-surgical blood samples were analyzed using TEG parameters, including Maximum Amplitude (MA), Citrated Functional Fibrinogen (CFF), and Functional Fibrinogen Levels (FLEV). Statistical analysis employed Kruskal-Wallis tests. RESULTS: Among 254 patients (182 with GFR >60, 56 with GFR 30-59, and 16 with GFR <30), those with declining kidney function showed progressively higher values in CRT MA (62.80 vs. 65.85 vs. 67.85 mm, P = 0.0021), CK MA (61.10 vs. 64.00 vs. 66.70 mm, P = 0.0063), CFF MA (21.40 vs. 24.10 vs. 33.70 mm, P = 0.0017), and CFF FLEV (390.5 vs. 487.2 vs. 556.6 mg/dL, P = 0.0029). This pattern persisted in patients on mono antiplatelet therapy (MAPT). Patients receiving MAPT showed consistently higher coagulation marker levels compared to those on dual antiplatelet therapy (DAPT), particularly in severe renal impairment (GFR <30). CONCLUSION: Patients with decreased kidney function demonstrated relative hypercoagulability compared to those with normal kidney function, as evidenced by elevated fibrinogen levels and stronger blood clots. While DAPT was associated with lower coagulation marker levels compared to MAPT, platelet reactivity remained similar across GFR categories. However, these laboratory findings did not translate into increased clinical events, with no significant differences in bleeding episodes (P = 0.436) or arterial thrombotic events (P = 0.095) across GFR categories.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cieri IF, Patel S, Rodriguez Alvarez AA, et al. Variability in Coagulation Profiles in Patients with Chronic Kidney Disease and Peripheral Artery Disease. Ann Vasc Surg. 2025. PMID: 39880280. doi:10.1016/j.avsg.2025.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。